The PPARs: From Orphan Receptors to Drug Discovery
The DOI matches its Crossref record; 215 of the 216 references it cites were found in a registry or an index.
Abstract
ADVERTISEMENT RETURN TO ISSUEPerspectiveNEXTThe PPARs: From Orphan Receptors to Drug Discovery†Timothy M. Willson, Peter J. Brown, Daniel D. Sternbach, and Brad R. HenkeView Author Information Department of Medicinal Chemistry, Glaxo Wellcome Research & Development, Research Triangle Park, North Carolina 27709 Cite this: J. Med. Chem. 2000, 43, 4, 527–550Publication Date (Web):February 24, 2000Publication History Received8 November 1999Published online24 February 2000Published inissue 1 February 2000https://pubs.acs.org/doi/10.1021/jm990554ghttps://doi.org/10.1021/jm990554greview-articleACS PublicationsCopyright © 2000 American Chemical SocietyRequest reuse permissionsArticle Views6740Altmetric-Citations1452LEARN ABOUT THESE METRICSArticle Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.Citations are the number of other articles citing this article, calculated by Crossref and updated daily. Find more information about Crossref citation counts.The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on the Altmetric Attention Score and how the score is calculated. Share Add toView InAdd Full Text with ReferenceAdd Description ExportRISCitationCitation and abstractCitation and referencesMore Options Share onFacebookTwitterWechatLinked InRedditEmail Other access optionsGet e-Alertsclose SUBJECTS:Agonists,Ligands,Lipids,Receptors,Rodent models Get e-Alerts
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Pemafibrate is an extremely selective PPARα agonist (subtype selectivity > 5000-fold for PPARγ and > 11,000-fold for PPARδ, respectively) [49, 50].”
From Pemafibrate, a new selective PPARα modulator: drug concept and its clinical applications for dyslipidemia and metabolic diseases (2020) · cites this paper as [50]
In the citing paper
“The PPARα activation by pemafibrate was > 2500 times stronger than fenofibric acid, the active form of fenofibrate.”
From Pemafibrate, a new selective PPARα modulator: drug concept and its clinical applications for dyslipidemia and metabolic diseases (2020) · cites this paper as [50]
Citations
Cites
Exploring the Metabolic and Genetic Control of Gene Expression on a Genomic Scale
DeRisi, J. L., Iyer, V. R., & Brown, P. O. (1997) · Science · doi:10.1126/science.278.5338.680 · Cited by 4,456
Self-citationA Cold-Inducible Coactivator of Nuclear Receptors Linked to Adaptive Thermogenesis
Puigserver, P., Wu, Z., Park, C. W., Graves, R., Wright, M., & Spiegelman, B. M. (1998) · Cell · doi:10.1016/s0092-8674(00)81410-5 · Cited by 3,864
Stimulation of adipogenesis in fibroblasts by PPARγ2, a lipid-activated transcription factor
Tontonoz, P., Hu, E., & Spiegelman, B. M. (1994) · Cell · doi:10.1016/0092-8674(94)90006-x · Cited by 3,529
The peroxisome proliferator-activated receptor-γ is a negative regulator of macrophage activation
Ricote, M., Li, A. C., Willson, T. M., Kelly, C. J., & Glass, C. K. (1998) · Nature · doi:10.1038/34178 · Cited by 3,525
Self-citationActivation of a member of the steroid hormone receptor superfamily by peroxisome proliferators
Issemann, I., & Green, S. (1990) · Nature · doi:10.1038/347645a0 · Cited by 3,519
Rubins, H. B., Robins, S. J., Collins, D., Fye, C. L., Anderson, J. W., Elam, M. B., Faas, F. H., Linares, E., Schaefer, E. J., Schectman, G., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908053410604 · Cited by 3,439
PPAR-γ agonists inhibit production of monocyte inflammatory cytokines
Jiang, C., Ting, A. T., & Seed, B. (1998) · Nature · doi:10.1038/34184 · Cited by 2,899
15-Deoxy-Δ12,14-Prostaglandin J2 is a ligand for the adipocyte determination factor PPARγ
Forman, B. M., Tontonoz, P., Chen, J., Brun, R. P., Spiegelman, B. M., & Evans, R. M. (1995) · Cell · doi:10.1016/0092-8674(95)90193-0 · Cited by 2,858
Braissant, O., Foufelle, F., Scotto, C., Dauça, M., & Wahli, W. (1996) · Endocrinology · doi:10.1210/endo.137.1.8536636 · Cited by 2,217
mPPAR gamma 2: tissue-specific regulator of an adipocyte enhancer.
Tontonoz, P., Hu, E., Graves, R. A., Budavari, A. I., & Spiegelman, B. M. (1994) · Genes & Development · doi:10.1101/gad.8.10.1224 · Cited by 2,181
Research works printed but not linked: 124
- Lichtenstein A. H., 1998, Nutr. Rev., 56, S28
- Harris M. I., 1998, Diabetes Care, 21, 524
- Howard B. V., 1995, Int. Congr. Ser.
- Barzilai N., 1999, J. Gerontol., Ser. A, 54, B96
- Lichtenstein A. H., 1999, Nutr. Rev., 57, 14
- Jump D. B., 1999, Annu. Rev. Nutr., 19, 90
- Mangelsdorf D. J., 1995, Cell, 83, 850
- A, 1999, Cell, 97, 163
- Xu H. E., 1999, Mol. Cell, 3, 403
- Hu E., 1996, Science, 274, 2103
- Zhang B., 1996, J. Biol. Chem., 271, 31774
- Adams M., 1997, J. Biol. Chem., 272, 5132
- Camp H. S., 1999, Endocrinology, 140, 397
- Juge-Aubry C. E., 1999, J. Biol. Chem., 274, 10510
- McDonnell D. P., 1993, Bio/Technology, 11, 1261
- Lehmann J. M., 1995, J. Biol. Chem., 270, 12956
- Xu L., 1999, Curr. Opin. Genet. Dev., 9, 147
- Zhu Y., 1996, Gene Expression, 6, 195
- Dowell P., 1997, J. Biol. Chem., 272, 33443
- Zhu Y., 1997, J. Biol. Chem., 272, 25506
- Yuan C.-X., 1998, Proc. Natl. Acad. Sci. U.S.A., 95, 7944
- Treuter E., 1998, Mol. Endocrinol., 12, 881, 10.1210/mend.12.6.0123 · doi:10.1210/mend.12.6.0123 · Paper page
- Krey G., 1997, Mol. Endocrinol., 11, 791, 10.1210/mend.11.6.0007 · DOI · Paper page
- Zhou G., 1998, Mol. Endocrinol., 12, 1604, 10.1210/mend.12.10.0176 · doi:10.1210/mend.12.10.0176 · Paper page
- Berger J., 1996, Endocrinology, 137, 4195
- Young P. W., 1998, J. Pharmacol. Exp. Ther., 284, 759
- Bell A. R., 1998, Biochem. J., 332, 693
- Heuvel J. P. V, 1999, Toxicol. Sci., 47, 8
- Palmer C. N. A., 1998, Mol. Pharmacol., 53, 22
- Gervois P., 1999, Mol. Endocrinol., 13, 1549
- Gaw A., 1994, Handb. Exp. Pharmacol., 109, 348
- Brown P. J., 1997, Synthesis, 778, 782
- Brown P. J., 1999, J. Med. Chem., 42, 3788
- Forman B. M., 1997, Proc. Natl. Acad. Sci. U.S.A., 94, 4317
- Yu K., 1995, J. Biol. Chem., 270, 23983
- Palmer C. N. A., 1994, J. Biol. Chem., 269, 18089
- Lee S. S.-T., 1995, Mol. Cell. Biol., 15, 3022
- Peters J. M., 1997, J. Biol. Chem., 272, 27312
- Gaw A., 1999, Lipoproteins Health Dis., 1145, 1160
- Ross S. D., 1999, Arch. Intern. Med., 159, 1802
- Oliver M. F., 1984, Lancet, 2, 604
- Rutolo G., 1998, J. Am. Coll. Cardiol., 32, 1656
- Libby P., 1999, Mol. Basis Cardiovasc. Dis., 349, 366
- Spencer N. F. L., 1997, Int. Immunol., 9, 1588
- Delerive P., 1999, J. Biol. Chem., 45, 32054
- Vazquez M., 1995, Br. J. Pharmacol., 116, 2075
- Jacobsson A., 1985, J. Biol. Chem., 260, 16254
- Krook A., 1998, Diabetes, 47, 1531
- Ruyter B., 1997, Biochim. Biophys. Acta, 1348, 338
- Zhu Y., 1993, J. Biol. Chem., 268, 26820
- Greene M. E., 1995, Gene Expression, 4, 299
- Chawla A., 1994, Endocrinology, 135, 800, 10.1210/endo.135.2.8033830 · doi:10.1210/endo.135.2.8033830 · Paper page
- Saladin R., 1999, Cell Growth Differ., 10, 48
- Martin G., 1997, J. Biol. Chem., 272, 28217
- Hofmann C., 1994, Endocrinology, 134, 270, 10.1210/endo.134.1.8275942 · DOI · Paper page
- Tai T.-A. C., 1996, J. Biol. Chem., 271, 29914
- Kelly L. J., 1998, Endocrinology, 139, 4927
- Hulin B., 1996, Curr. Pharm. Des., 2, 102
- Kletzien R. F., 1992, Mol. Pharmacol., 41, 398
- Ibrahimi A., 1994, Mol. Pharmacol., 46, 1076
- Harris P. K. W., 1994, Mol. Pharmacol., 45, 445
- Willson T. M., 1996, J. Med. Chem., 39, 668
- Ide T., 1998, Diabetes Front, 9, 346
- Shinkai H., 1998, J. Med. Chem., 41, 1933
- Reginato M. J., 1998, J. Biol. Chem., 273, 32684
- Reddy K. A., 1999, J. Med. Chem., 42, 3278
- Sohda T., 1984, Chem. Pharm. Bull., 32, 4465
- Buckle D. R., 1996, Bioorg. Med. Chem. Lett., 6, 2126
- Buckle D. R., 1996, Bioorg. Med. Chem. Lett., 6, 2130
- Henke B. R., 1998, Discovery of a novel series of potent antihyperglycemic and antihyperlipidemic agents. J. Med. Chem
- Collins J. L., 1998, Structure−activity relationship and optimization of the phenyl alkyl ether moiety. J. Med. Chem
- Cobb J. E., 1998, N-(2-Benzoylphenyl)-l-tyrosine PPARγ agonists. 3. Structure−activity relationship and optimization of the N-aryl substituent. J. Med. Chem., 41, 5069
- Lehmann J. M., 1997, J. Biol. Chem., 272, 3410
- Verrando P., 1981, Biochim. Biophys. Acta, 663, 265
- Negishi M., 1995, J. Lipid Mediators Cell Signalling, 12, 448
- Narumiya S., 1991, Dev. Oncol., 67, 448
- Ikeda H., 1990, Arzneim.-Forsch., 40, 162
- Horikoshi H., 1994, Annu. Rep. Sankyo Res. Lab., 46, 57
- Prigeon R. L., 1998, J. Clin. Endocrinol. Metab., 83, 823
- Fonseca V. A., 1998, J. Clin. Endocrinol. Metab., 83, 3176
- Spencer C. M., 1997, Drugs, 54, 101
- Kumar S., 1996, Diabetologia, 39, 709
- Gimble J. M., 1996, Mol. Pharmacol., 50, 1094
- Jones S. A., 2000, Mol. Endocrinol., 14, 39, 10.1210/mend.14.1.0409 · doi:10.1210/mend.14.1.0409 · Paper page
- Blumberg B., 1998, Genes Dev., 12, 3205
- Ramachandran V., 1999, Drug Metab. Dispos., 27, 1199
- Yamazaki H., 1999, Drug Metab. Dispos., 27, 1266
- Pumford N. R., 1997, Annu. Rev. Pharmacol. Toxicol., 37, 117
- Miller V. A., 1997, J. Clin. Oncol., 15, 795
- Rizvi N. A., 1999, Clin. Cancer Res., 5, 1664
- Vidal-Puig A. J., 1997, J. Clin. Invest., 99, 2422
- Park K. S., 1997, Diabetes, 46, 1234
- Wu Z., 1998, J. Clin. Invest., 101, 32
- Sreenan S., 1999, Am. J. Physiol., 276, E1129
- Miles P. D. G., 1997, Diabetes, 46, 1683
- Yen C.-J., 1997, Biochem. Biophys. Res. Commun., 241, 274
- Deeb S. S., 1998, Nat. Genet., 20, 287
- Valve R., 1999, J. Clin. Endocrinol. Metab., 84, 3712
- Mori Y., 1998, Biochem. Biophys. Res. Commun., 251, 198
- Ek J., 1999, Diabetologia, 42, 895
- Hamann A., 1999, Eur. J. Endocrinol., 141, 92
- Girard J, 1997, Diabetes Metab., 23, 24
- McKeigue P., 1997, Handb. Hypertens., 17, 934
- Dubey R. K., 1993, Am. J. Physiol., 265, R732
- Zhang H. Y., 1994, Hypertension, 24, 110
- Morikang E., 1997, Am. J. Hypertens., 10, 446
- Law R. E., 1996, J. Clin. Invest., 98, 1905
- Kotchen T. A., 1996, Am. J. Physiol., 270, R666
- Zhang F., 1994, Hypertension, 24, 175
- Su C. G., 1999, J. Clin. Invest., 104, 389
- Ehrmann D. A., 1997, J. Clin. Endocrinol. Metab., 82, 2116
- Minamikawa J., 1998, J. Clin. Endocrinol. Metab., 83, 1820
- Suh N., 1999, Cancer Res., 59, 5673
- Lefebvre A.-M., 1998, Nat. Med., 4, 1057
- Schmidt A., 1992, Mol. Endocrinol., 6, 1641
- Amri E.-Z., 1995, J. Biol. Chem., 270, 2371
- Brooks C. D. W., 1996, J. Med. Chem., 39, 2654
- Brun R. P., 1996, Genes Dev., 10, 984
- Lim H., 1999, Genes Dev., 13, 1574
- He T.-C., 1999, Cell, 99, 345
- Cobb J., 1998, Annu. Rep. Med. Chem., 33, 222
- Sliskovic D. R., 1999, Annu. Rep. Med. Chem., 34, 110
- Belch J. J. F., 1998, Proc. Nutr. Soc., 57, 569
- Woutersen R. A., 1999, Mutat. Res., 443, 127
Cited by
Items 601–700 of 1,003
Potential mechanisms of formononetin against inflammation and oxidative stress: a review
Ding, M., Bao, Y., Liang, H., Zhang, X., Li, B., Yang, R., & Zeng, N. (2024) · Frontiers in Pharmacology · doi:10.3389/fphar.2024.1368765 · Cited by 55
“PPAR γ is a member of the nuclear hormone receptor transcription factor superfamily and is an active participant in the regulation of genes involved in metabolism, in fl ammation, immunity, cell proliferation and differentiation (Willson et al., 2000; Schupp et al., 2009; Rogue et al., 2010).”
BackgroundStahel, P. F., Smith, W. R., Bruchis, J., & Rabb, C. H. (2008) · PPAR Research · doi:10.1155/2008/538141 · Cited by 52
“PPARs are activated by naturally ocurring fatty acid derivatives, eicosanoides, and by synthetic pharmacological agents, such as fibrates (PPARα) and glitazones (PPARγ) [18, 22, 43].”
Jia, B., Madsen, L., Petersen, R. K., Techer, N., Kopperud, R. K., Ma, T., Døskeland, S. O., Ailhaud, G. P., Wang, J., Amri, E., et al. (2012) · PLoS ONE · doi:10.1371/journal.pone.0034114 · Cited by 54
“A difference in binding affinity between human and murine PPARa may in part explain this difference [47,48].”
Yin, Y., Yuan, H., Wang, C., Pattabiraman, N., Rao, M., Pestell, R. G., & Glazer, R. I. (2005) · Molecular Endocrinology · doi:10.1210/me.2005-0197 · Cited by 55
Bojic, L. A., Sawyez, C. G., Telford, D. E., Edwards, J. Y., Hegele, R. A., & Huff, M. W. (2012) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.112.255208 · Cited by 51
“High doses of PPAR agonists can activate PPAR isoforms nonselectively.(25,26) Therefore, we determined the PPARδspecificity of the concentrations of agonists used.”
BackgroundAllosteric Pathways in the PPARγ-RXRα nuclear receptor complex
Ricci, C. G., Silveira, R. L., Rivalta, I., Batista, V. S., & Skaf, M. S. (2016) · Scientific Reports · doi:10.1038/srep19940 · Cited by 56
Fibrates in the management of atherogenic dyslipidemia
Okopień, B., Bułdak, Ł., & Bołdys, A. (2017) · Expert Review of Cardiovascular Therapy · doi:10.1080/14779072.2017.1408410 · Cited by 53
“Bezafibrate has the ability to stimulate PPA- gamma receptors and as a result the greatest influence on carbohydrate metabolism [36].”
BackgroundDiet, fatty acids, and regulation of genes important for heart disease
Heuvel, J. P. V. (2004) · Current Atherosclerosis Reports · doi:10.1007/s11883-004-0083-9 · Cited by 55
“However, fatty acids are weak a ctivators of this receptor, with roughly the same preference as PPARα [ 23 ].”
BackgroundInfluentialCommonalities in the Association between PPARG and Vitamin D Related with Obesity and Carcinogenesis
Bandera-Merchán, B., Tinahones, F. J., & Macías‐González, M. (2016) · PPAR Research · doi:10.1155/2016/2308249 · Cited by 53
“[5] T.”
BackgroundBervejillo, M. L., & Ferreira, A. M. (2019) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-11488-6_3 · Cited by 52
Peroxisome Proliferator-Activated Receptors and the Cardiovascular System
Chen, Y. E., Fu, M., Zhang, J., Zhu, X., Lin, Y., Akinbami, M. A., & Song, Q. (2003) · Vitamins and hormones · doi:10.1016/s0083-6729(03)01005-7 · Cited by 53
Epple, R., Cow, C., Yongping, X., Azimioara, M. D., Russo, R., Wang, X., Wityak, J., Karanewsky, D. S., Tuntland, T., Nguyen-Tran, V. T. B., et al. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm9007399 · Cited by 50
Hopkins, C. R., O’Neil, S. V., Laufersweiler, M. C., Wang, Y., Pokross, M. E., Mekel, M. J., Evdokimov, A. G., WALTER, R. D., Kontoyianni, M., Petrey, M. E., et al. (2006) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2006.08.003 · Cited by 50
Aspirin increases CD36, SR-BI, and ABCA1 expression in human THP-1 macrophages
Viñals, M. L., Bermúdez-Escobar, I. C., Llaverías, G., Alegret, M., SANCHEZ, R., Vázquez‐Carrera, M., & Laguna, J. C. (2005) · Cardiovascular Research · doi:10.1016/j.cardiores.2004.12.024 · Cited by 55
“fibrates [8] and PPARg binds the antidiabetic glitazones [10].”
BackgroundTakeda, M., Otsuka, F., Otani, H., Inagaki, K., Miyoshi, T., Suzuki, J., Mimura, Y., Ogura, T., & Makino, H. (2007) · Journal of Endocrinology · doi:10.1677/joe-07-0138 · Cited by 50
“PPAR g is activated after the binding of natural ligands such as polyunsaturated fatty acids and prostaglandin metabolites (Willson et al. 2000).”
BackgroundCathcart, M. C., O'Byrne, K. J., Reynolds, J. V., O'Sullivan, J. N., & Pidgeon, G. P. (2011) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2011.09.004 · Cited by 51
“Three distinct isotypes of PPARs have been identified to date and may be generally designated as PPARα, PPARβ/δ and PPARγ [60, 61] (Fig.”
BackgroundRetinoids inhibit differentiation of hematopoetic osteoclast progenitors
Conaway, H. H., Persson, E., Halen, M., Granholm, S., Svensson, O., Pettersson, U., Lie, A., & Lerner, U. H. (2009) · The FASEB Journal · doi:10.1096/fj.09-132548 · Cited by 52
Rosiglitazone inhibits mouse liver regeneration
Turmelle, Y. P., Shikapwashya, O., Tu, S., Hruz, P. W., Yan, Q., & Rudnick, D. A. (2006) · The FASEB Journal · doi:10.1096/fj.06-6511fje · Cited by 51
“Taken together, these observations indicate that thiazolidinediones impair hepatocellular BrdU incorporation, cyclin expression, and mitotic progression during liver regeneration with efficacies that correspond to their potencies of PPAR -activation (22, 26).”
Discovery of INT131: A selective PPARγ modulator that enhances insulin sensitivity
Taygerly, J. P., McGee, L. R., Rubenstein, S. M., Houze, J. B., Cushing, T. D., Li, Y., Motani, A. S., Chen, J., Frankmoelle, W. P., Ye, G., et al. (2012) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2012.11.058 · Cited by 49
Lebovic, D. I., Mwenda, J. M., Chai, D. C., Santi, A., Xu, X., & D'Hooghe, T. (2010) · Endocrinology · doi:10.1210/en.2009-1076 · Cited by 47
Peng, X., Gennemark, P., O’Mahony, G., & Bartesaghi, S. (2015) · Frontiers in Endocrinology · doi:10.3389/fendo.2015.00174 · Cited by 55
A new insight into the treatment of diabetes by means of pan PPAR agonists
Chandra, A., Kaur, P., Sahu, S. K., & Mittal, A. (2022) · Chemical Biology & Drug Design · doi:10.1111/cbdd.14020 · Cited by 50
“3.8.3 | Bezafibrate Bezafibrate is a pan PPAR agonist (Willson et al., 2000b).”
BackgroundInfluentialSivarajah, A., McDonald, M. C., & Thiemermann, C. (2005) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.104.080598 · Cited by 49
“, 1998), and there is a good correlation between the potency of the TZDs as PPAR- agonists in vitro and their efficacy at lowering glucose levels in vivo (Willson et al., 2000).”
BackgroundFoucher, C., Rattier, S., Flavell, D. M., Talmud, P. J., Humphries, S. E., Kastelein, J. J. P., Ayyobi, A. F., Pimstone, S. N., Frohlich, J. J., Ansquer, J.-C., et al. (2004) · Pharmacogenetics · doi:10.1097/00008571-200412000-00005 · Cited by 49
Kanakasabai, S., Walline, C. C., Chakraborty, S., & Bright, J. J. (2010) · Brain Research · doi:10.1016/j.brainres.2010.12.059 · Cited by 50
“…and to test the efficacy of potential therapeutic agents for the treatment of MS. Peroxisome proliferator-activated receptors (PPARs) are a family of nuclear receptor transcription factors that play key roles in the regulation of development, metabolism and inflammation (Willson et al., 2000).”
Prevention of colorectal cancer through the use of COX-2 selective inhibitors
Peek, R. M. (2004) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-004-0887-x · Cited by 56
“PPARa, PPARd, and PPARc constitute a family of nuclear hormone receptors with important roles in the regulation of fatty acid oxidation and glucose utilization [21, 60 ].”
BackgroundPeroxisome Proliferator Activated Receptors
Genolet, R., Michalik, L., & Wahli, W. (2005) · Springer eBooks · doi:10.1007/3-540-27194-5_22 · Cited by 49
“In addition to these biological ligands, selective synthetic ligands have been developed for each isotype, which are used as experimental activators or drugs [67].”
BackgroundDietary and metabolic effects on intestinal stem cells in health and disease
Shay, J. E. S., & Yilmaz, Ö. H. (2024) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-024-00980-7 · Cited by 63
Cho, S. W., Yang, J., Her, S. J., Choi, H. J., Jung, J. Y., Sun, H. J., An, J. H., Cho, H. Y., Kim, S. W., Park, K. S., et al. (2011) · Journal of Bone and Mineral Research · doi:10.1002/jbmr.366 · Cited by 48
Jones, A., Kulozik, P., Ostertag, A., & Herzig, S. (2009) · Journal of Alzheimer's Disease · doi:10.3233/jad-2009-0973 · Cited by 48
“It has also been shown that PPAR γ is a potent target of some NSAIDs [259,260] and the induction of PPAR γ by NSAIDs reduces A β levels in cells and animal models [261].”
Jeninga, E. H., van Beekum, O., van Dijk, A. D. J., Hamers, N., Hendriks-Stegeman, B. I., Bonvin, A. M. J. J., Berger, R., & Kalkhoven, E. (2007) · Molecular Endocrinology · doi:10.1210/me.2006-0485 · Cited by 52
“Synthetic PPAR agonists include the thiazolidinediones (TZDs) (25) and tyrosine-based agonists (26), which ameliorate insulin resistance and lower blood glucose levels in patients with type 2 diabetes (8).”
Mechanisms of action, chemical characteristics, and model systems of obesogens
Griffin, M. D., Pereira, S. R., DeBari, M. K., & Abbott, R. D. (2020) · BMC Biomedical Engineering · doi:10.1186/s42490-020-00040-6 · Cited by 52
“This results in an increase in mRNA expression of the target gene [28, 29, 31, 32].”
BackgroundStrategies in the Search for New Lead Compounds or Original Working Hypotheses
Wermuth, C. G., Villoutreix, B. O., Grisoni, S., Olivier, A., & Rocher, J. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-417205-0.00004-3 · Cited by 55
Zhang, B. B. (2002) · Frontiers in Bioscience · doi:10.2741/a820 · Cited by 47
The Role of Peroxisome Proliferator-Activated Receptors in Colorectal Cancer
Park, J., & Kwak, J. (2012) · PPAR Research · doi:10.1155/2012/876418 · Cited by 53
“This effect is probably mediated through the binding of PPARγ on PPRE in the promoter of PTEN [48].”
Backgroundα-Lipoic acid: physiologic mechanisms and indications for the treatment of metabolic syndrome
Pershadsingh, H. A. (2007) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.16.3.291 · Cited by 54
“The discovery that TZDs were high-affinity agonists for PPAR-γ led to the proposal that ligand-dependent modulation of gene transcription through PPAR-γ activation is an important pharmacologic target in the treatment of diabetes [55,56] and the metabolic syndrome [57,58].”
BackgroundDeng, T., Shan, S., Li, Z.-B., Wu, Z.-W., Liao, C., Ko, B. C. B., Lu, X.-P., Cheng, J., & Ning, Z.-Q. (2005) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.28.1192 · Cited by 50
The Role of Thiazolidinediones in the Treatment of Patients with Type 2 Diabetes Mellitus
Mooradian, A. D., Chehade, J. M., & Thurman, J. E. (2002) · Treatments in Endocrinology · doi:10.2165/00024677-200201010-00002 · Cited by 48
Additivity of Molecular Fields: CoMFA Study on Dual Activators of PPARα and PPARγ
Khanna, S., Sobhia, M. E., & Bharatam, P. V. (2005) · Journal of Medicinal Chemistry · doi:10.1021/jm049383s · Cited by 48
Díaz‐García, D., Ferrer-Donato, Á., Méndez‐Arriaga, J. M., Cabrera-Pinto, M., Díaz‐Sánchez, M., Prashar, S., Fernández-Martos, C. M., & Gómez‐Ruiz, S. (2022) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.2c00865 · Cited by 47
Porcelli, L., Gilardi, F., Laghezza, A., Piemontese, L., Mitro, N., Azzariti, A., Fabio Altieri, F., Cervoni, L., Fracchiolla, G., Giudici, M., et al. (2011) · Journal of Medicinal Chemistry · doi:10.1021/jm201306q · Cited by 50
García-Bates, T. M., Bernstein, S. H., & Phipps, R. P. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0457 · Cited by 54
PPARα-dependent exacerbation of experimental colitis by the hypolipidemic drug fenofibrate
Qi, Y., Jiang, C., Tanaka, N., Krausz, K. W., Brocker, C. N., Fang, Z.-Z., Bredell, B. X., Shah, Y. M., & Gonzalez, F. J. (2014) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00153.2014 · Cited by 50
“Fibrates such as fenofibrate are PPAR agonists and have been used for several decades as hypolipidemic therapeutic agents (6, 53).”
Backgroundtrans-Caryophyllene is a natural agonistic ligand for peroxisome proliferator-activated receptor-α
Wu, C., Jia, Y., Lee, J. H., Jun, H., Lee, H.-S., Hwang, K.-Y., & Lee, S. (2014) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2014.04.112 · Cited by 54
Niu, H., Wang, W., Li, J., Lei, Y., Zhao, Y., Yang, W., Zhao, C., Lin, B., Song, S., & Wang, S. (2017) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2017.06.033 · Cited by 47
Noguchi, T., Kobayashi, J., Yagi, K., Nohara, A., Yamaaki, N., Sugihara, M., Ito, N., Oka, R., Kawashiri, M., Tada, H., et al. (2011) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2011.02.012 · Cited by 49
Rikimaru, K., Wakabayashi, T., Abe, H., Imoto, H., Maekawa, T., Ujikawa, O., Murase, K., Matsuo, T., Matsumoto, M., Nomura, C., et al. (2011) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2011.12.008 · Cited by 52
Macrovascular complications of metabolic syndrome: an early intervention is imperative
Tenenbaum, A., Motro, M., Schwammenthal, E., & Fisman, E. Z. (2004) · International Journal of Cardiology · doi:10.1016/j.ijcard.2003.07.033 · Cited by 50
“However, our understanding of the metabolic syndrome has been improved with the discovery of nuclear PPARs [17,18,24–26].”
Fenofibrate and Heart Failure Outcomes in Patients With Type 2 Diabetes: Analysis From ACCORD
Ferreira, J. P., Vasques‐Nóvoa, F., Ferrão, D., Saraiva, F. A., Falcão‐Pires, I., Neves, J. S., Sharma, A., Rossignol, P., Zannad, F. M., & Leite-Moreira, A. F. (2022) · Diabetes Care · doi:10.2337/dc21-1977 · Cited by 49
Wang, J., Wei, Y., Wang, D., Chan, L. L., & Dai, J. (2007) · Ecotoxicology · doi:10.1007/s10646-007-0187-4 · Cited by 48
“Three subtypes of PPAR (-alpha, -beta, and -gamma) have been identified in mammals and they play key roles in lipid metabolism and energy homeostasis (Berger et al. 2005; Desvergne et al. 2004; Willson et al. 2000; Dreyer et al. 1992; Kliewer et al. 1994).”
BackgroundJeong, S., Chae, K., Jung, Y. S., Rho, Y. H., Lee, J., Ha, J., Yoon, K. H., Kim, G. C., Oh, K. S., Shin, S. S., et al. (2008) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2008.06.037 · Cited by 47
Early investigational drugs targeting PPAR-α for the treatment of metabolic disease
Liu, Z.-M., Hu, M., Chan, P., & Tomlinson, B. (2015) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2015.1006359 · Cited by 45
“Similar findings were noted in the secondary prevention Bezafibrate Infarction Prevention study where bezafibrate did not significantly reduce the primary end point in the overall study but did reduce it in a sub group of patients with high baseline triglycerides (‡ 200 mg/dl or 2.3 mmol/l) and in a later analysis ide…”
InfluentialPhenoxy Herbicides and Fibrates Potently Inhibit the Human Chemosensory Receptor Subunit T1R3
Maillet, É. L., Margolskee, R. F., & Mosinger, B. J. (2009) · Journal of Medicinal Chemistry · doi:10.1021/jm900823s · Cited by 46
Shen, L., Zhang, Y., Wang, A., Sieber-McMaster, E. S., Chen, X., Pelton, P. D., Xu, J., Yang, M., Zhu, P., Zhou, L., et al. (2007) · Journal of Medicinal Chemistry · doi:10.1021/jm070511x · Cited by 46
Hašková, Z., Hoang, B. Q., Luo, G., Morgan, L. A., Billin, A. N., Barone, F. C., SHEARER, B. G., Barton, M. E., & Kilgore, K. S. (2008) · Inflammation Research · doi:10.1007/s00011-007-7157-4 · Cited by 47
“Peroxisome proliferator-activated receptors (PPARs) are members of the steroid hormone nuclear receptor family [ 1 ] with three primary isoforms; a, g and d (also known as b/d).”
BackgroundHomo and Heterodimer Ligands: the Twin Drug Approach
Contreras, J., & Sippl, W. (2008) · Elsevier eBooks · doi:10.1016/b978-0-12-374194-3.00018-4 · Cited by 48
Manna, M. K., Bairy, G., & Jana, R. (2017) · Organic & Biomolecular Chemistry · doi:10.1039/c7ob01418j · Cited by 45
Targeting PPARα for the Treatment and Understanding of Cardiovascular Diseases
Li, S., Yang, B., Du, Y., Lin, Y., Liu, J., Huang, S., Zhang, A., Jia, Z., & Zhang, Y. (2018) · Cellular Physiology and Biochemistry · doi:10.1159/000495969 · Cited by 45
Sameeh, M. Y., Khowdiary, M. M., Nassar, H. S., Abdelall, M. M., Alderhami, S. A., & Elhenawy, A. A. (2021) · Biomedicines · doi:10.3390/biomedicines10010024 · Cited by 47
“HIS 449, SER299, HIS323, CYS285,ASP300, Arg195) and (Asp300, Glu233 and Asp197) for (PPAR-γ, PDB: 2PRG [55]) and (α-amylase, PDB:2QV4 [56]), respectively.”
Willems, S., & Merk, D. (2022) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.2c00585 · Cited by 46
Tanaka, A., Hirohara, J., Nakanuma, Y., Tsubouchi, H., & Takikawa, H. (2015) · Journal of Gastroenterology · doi:10.1007/s00535-014-0998-z · Cited by 44
“Bezafibrate, a ligand of nuclear peroxisome-proliferatoractivated receptor a and other isoforms [8], was originally labeled as a drug for treatment of hyperlipidemia and used for prevention of cardiovascular diseases.”
MethodCharacterization of New PPARγ Agonists: Analysis of Telmisartan’s Structural Components
Goebel, M., Clemenz, M., Staels, B., Unger, T., Kintscher, U., & Gust, R. (2009) · ChemMedChem · doi:10.1002/cmdc.200800285 · Cited by 48
Wu, Y., & Guo, S. (2008) · Fertility and Sterility · doi:10.1016/j.fertnstert.2008.04.012 · Cited by 46
Stanley, T. B., Leesnitzer, L. M., Montana, V. G., Galardi, C. M., Lambert, M. H., Holt, J. A., Xu, H. E., Moore, L. B., Blanchard, S. G., & Stimmel, J. B. (2003) · Biochemistry · doi:10.1021/bi034472c · Cited by 45
Xu, Y., Rito, C. J., Etgen, G. J., Ardecky, R., Bean, J. S., Bensch, W. R., Bosley, J. R., Broderick, C. L., Brooks, D. A., Dominianni, S. J., et al. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm0342616 · Cited by 47
Olsson, U., Egnell, A.-C., Lee, M. R., Lundén, G. O., Lorentzon, M., Salmivirta, M., Bondjers, G., & Camejo, G. (2001) · Diabetes · doi:10.2337/diabetes.50.9.2126 · Cited by 44
“The concentrations of darglitazone and bezafibrate used usually show effects in vitro (7,19).”
BackgroundMiglio, G., Rosa, A. C., Rattazzi, L., Grange, C., Collino, M., Camussi, G., & Fantozzi, R. (2010) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2010.01032.x · Cited by 46
“Notably, the EC50s were similar to those reported in transactivation assays (Willson et al., 2000; Mukherjee et al., 2002; Sznaidman et al., 2003).”
BackgroundAmbrosino, P., Soldovieri, M. V., Maria, M. D., Russo, C., & Taglialatela, M. (2014) · Pharmacological Research · doi:10.1016/j.phrs.2014.06.015 · Cited by 44
Idrees, G. A., Aly, O. M., Abuo‐Rahma, G. E. A., & Radwan, M. F. (2009) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2009.04.026 · Cited by 44
Design and synthesis of novel indole-chalcone fibrates as lipid lowering agents
Sashidhara, K. V., Dodda, R. P., Sonkar, R., Palnati, G. R., & Bhatia, G. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.04.085 · Cited by 46
Romano, A., Tempesta, B., Provensi, G., Passani, M. B., & Gaetani, S. (2015) · Frontiers in Pharmacology · doi:10.3389/fphar.2015.00137 · Cited by 53
“This evidence further points to the role of endogenous OEA in the small intestine as a local satiety messenger.”
Yang, Q., Kurotani, R., Yamada, A., Kimura, S., & Gonzalez, F. J. (2006) · Endocrinology · doi:10.1210/en.2006-0437 · Cited by 44
Genest, D., Garnier, N., Arrault, A., Marot, C., Morin‐Allory, L., & Genest, M. (2007) · European Biophysics Journal · doi:10.1007/s00249-007-0220-9 · Cited by 46
“They are found as three homologous isoforms: alpha, delta and gamma (Willson et al. 2000).”
Peroxisome proliferator-activated receptors gamma ligands and ischemia and reperfusion injury
Cuzzocrea, S. (2004) · Vascular Pharmacology · doi:10.1016/j.vph.2004.10.004 · Cited by 45
Jakobsen, M. A., Petersen, R. K., Kristiansen, K., Lange, M., & Lillevang, S. T. (2006) · Scandinavian Journal of Immunology · doi:10.1111/j.1365-3083.2006.01745.x · Cited by 49
The farnesoid X receptor: a novel drug target?
Claudel, T., Sturm, E., Kuipers, F., & Staels, B. (2004) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.13.9.1135 · Cited by 47
“The peroxisome proliferator-activated receptor-α (PPAR-α) is a nuclear receptor activated by FAs [88] that mediates the lipid-lowering effect of the fibrates [89].”
BackgroundAntidiabetic and hypolipidemic potential of DRF 2519—a dual activator of PPAR-α and PPAR-γ
Chakrabarti, R., Misra, P., Vikramadithyan, R. K., Mamnoor, P., Hiriyan, J., Datla, S. R., Damarla, R. K. B., Suresh, J., & Rajagopalan, R. (2004) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2004.03.034 · Cited by 46
Yamashita, S., Rizzo, M., Su, T., & Masuda, D. (2023) · Metabolites · doi:10.3390/metabo13050626 · Cited by 44
“Pemafibrate is extremely selective for PPARα (>5000-fold for PPARγ and >11,000-fold for PPARδ, respectively) [35,36].”
BackgroundRole of Peroxisome Proliferator-Activated Receptor γ in Ocular Diseases
Zhang, S., Gu, H., & Hu, N. (2015) · Journal of Ophthalmology · doi:10.1155/2015/275435 · Cited by 45
“[137] T.”
Process Development and Scale-Up of the PPAR Agonist NNC 61-4655
Deussen, H.-J., Jeppesen, L., Schärer, N., Junager, F., Bentzen, B., Weber, B., Weil, V., Mozer, S. J., & Sauerberg, P. (2004) · Organic Process Research & Development · doi:10.1021/op034048j · Cited by 43
Wagner, J. A., Wright, E. C., Ennis, M. M., PRINCE, M. J., Kochan, J. P., Nunez, D. J., Schneider, B., Wang, M.-D., Chen, Y., Ghosh, S., et al. (2009) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2009.88 · Cited by 43
Luo, Y., Yang, P., Li, Z., Luo, Y., Shen, J., Li, R., Zheng, H., Liang, Y., & Xia, N. (2019) · Drug Design Development and Therapy · doi:10.2147/dddt.s224688 · Cited by 44
“The peroxisome proliferator-activated receptors (PPARs) are members of the nuclear receptor superfamily that function as fatty acid-activated transcription factors.(22) PPAR activation may limit inflammation and atherosclerosis.”
BackgroundVallianatou, T., Giaginis, C., & Tsantili‐Kakoulidou, A. (2014) · Advances in experimental medicine and biology · doi:10.1007/978-3-319-08927-0_21 · Cited by 43
PPAR‐γ – a possible drug target for complicated pregnancies
McCarthy, F. P., Delany, A. C., Kenny, L. C., & Walsh, S. K. (2012) · British Journal of Pharmacology · doi:10.1111/bph.12069 · Cited by 48
“…regulate the expression of a number of genes involved in cell differentiation and proliferation (Mueller et al., 1998), energy homeostasis, fatty acid catabolism and adipogenesis (Kastner et al., 1994; Mangelsdorf et al., 1995; Escher and Wahli, 2000; Lazennec et al., 2000; Willson et al., 2000).”
BackgroundIdentification of a PPARδ agonist with partial agonistic activity on PPARγ
Connors, R., Wang, Z., Harrison, M., Zhang, A., Wanska, M., Hiscock, S., Fox, B. M., Dore, M., Labelle, M., Sudom, A. M., et al. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.04.151 · Cited by 47
Ye, F., Zhang, Z., Luo, H., Shen, J., Chen, K., Shen, X., & Jiang, H. (2005) · ChemBioChem · doi:10.1002/cbic.200500186 · Cited by 44
Factors influencing the differentiation of bovine preadipocytes in vitro1
Lengi, A. J., & Corl, B. A. (2010) · Journal of Animal Science · doi:10.2527/jas.2009-2439 · Cited by 48
Iqbal, M., Duffy, P., Evans, P., Cloughley, G., Allan, B. B., Lledó, A., Verdaguer, X., & Riéra, A. (2008) · Organic & Biomolecular Chemistry · doi:10.1039/b814619e · Cited by 48
Ward, J., & Tan, X. (2007) · PPAR Research · doi:10.1155/2007/14983 · Cited by 45
“Naturally occurring PPARγ ligands include polyunsaturated fatty acids (PUFAs), such as linoleic acid, arachidonic acid, and eicosapentanoic acids, and oxidised lipids such as 9and 13-hydroxyoctadecadienoic acid (HODE), and 12- and 15-HETE [10].”
Souza, A. T. D., Cornwell, P. D., Dai, X., Caguyong, M. J., & Ulrich, R. G. (2006) · Toxicological Sciences · doi:10.1093/toxsci/kfl019 · Cited by 44
“For the 908 genes, the responses of two compounds, rosiglitazone (a PPARc agonist) and retinoic acid (an RAR agonist), were used in the deselection strategy to rank PPARa activation specificity in a two-step process (A and B) as follows.”
BackgroundInfluentialSahebkar, A., & Watts, G. F. (2013) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2013.06.026 · Cited by 42
A potential role for cannabinoid receptors in the therapeutic action of fenofibrate
Priestley, R. S., Nickolls, S. A., Alexander, S. P. H., & Kendall, D. A. (2014) · The FASEB Journal · doi:10.1096/fj.14-263053 · Cited by 42
“Fenofibrate, therefore, is ;60 and 1400 times more potent at the CB1 and CB2 receptors, respectively, than at PPAR-a (EC50, 30mM)(25).”
BackgroundGoriya, Y., & Ramana, C. V. (2014) · Chemical Communications · doi:10.1039/c4cc02501f · Cited by 42
Teramoto, T., Shirai, K., Daida, H., & Yamada, N. (2012) · Cardiovascular Diabetology · doi:10.1186/1475-2840-11-29 · Cited by 43
“Moreover, previous research has shown that bezafibrate functions as an agonist of PPAR nuclear transcription factors, which play an important role in glucose and lipid metabolism [9-13].”
Thyroid Hormone and Skeletal Development
Gouveia, C. H. D. A., Miranda-Rodrigues, M., Martins, G. M., & Neofiti-Papi, B. (2018) · Vitamins and hormones · doi:10.1016/bs.vh.2017.06.002 · Cited by 47
Benzothiazole-based N-(phenylsulfonyl)amides as a novel family of PPARα antagonists
Ammazzalorso, A., Giancristofaro, A., D’Angelo, A., Filippis, B. D., Fantacuzzi, M., Giampietro, L., Maccallini, C., & Amoroso, R. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.06.028 · Cited by 42
Hong, G., Davis, B., Khatoon, N., Baker, S. F., & Brown, J. (2003) · Biochemical and Biophysical Research Communications · doi:10.1016/s0006-291x(03)00418-2 · Cited by 46
Kim, Y. H., & Han, H. J. (2007) · Stem Cells · doi:10.1634/stemcells.2007-0786 · Cited by 42
Askari, B., Carroll, M. A., Capparelli, M. F., Kramer, F., Gerrity, R. G., & Bornfeldt, K. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m205112200 · Cited by 42
Effects of rosiglitazone and high fat diet on lipase/esterase expression in adipose tissue
Shen, W., Patel, S., Yu, Z., Jue, D., & Kraemer, F. B. (2006) · Biochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids · doi:10.1016/j.bbalip.2006.11.009 · Cited by 44
“Kageyama H, Hirano T, Okada K, Ebara T, Kageyama A, Murakami T, Shioda S, Adachi M. Lipoprotein lipase mRNA in white adipose tissue but not in skeletal muscle is increased by pioglitazone through PPAR‐gamma.”
BackgroundInfluential
Metadata
- Authors
- Willson, T. M., Brown, P. J., Sternbach, D. D., & Henke, B. R.
- Affiliations
- Department of Medicinal Chemistry, Glaxo Wellcome Research & Development, Research Triangle Park, North Carolina 27709
- Venue
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Published
- 2000-02-01
- Volume
- 43
- Issue
- 4
- Pages
- 527-550
- ISSN
- 0022-2623 (ISSN-L)
- 1520-4804
- OpenAlex
- W1977666051
- Cited by
- 1,816
- References
- 216
- Citations by year
- 2026: 18 · 2025: 28 · 2024: 27 · 2023: 35 · 2022: 38 · 2021: 41 · 2020: 38 · 2019: 44 · 2018: 46 · 2017: 44 · 2016: 37 · 2015: 60 · 2014: 62 · 2013: 52 · 2012: 92
- FWCI
- 7.59
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Journal of Medicinal Chemistry (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Nuclear Receptors and Signaling
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Drug Discovery › Computational Drug Discovery Methods
- Keywords
- peroxisome proliferator-activated receptors, orphan receptors, drug discovery, receptor agonists, ligands, lipid signaling, nuclear receptors
- MeSH terms
- Animals, Diabetes Mellitus, Humans, Hyperlipidemias, Hypertension, Inflammation, Ligands, Models, Molecular, Neoplasms, Nuclear Proteins, Obesity, Transcription Factors, Drug Design, Receptors, Cytoplasmic and Nuclear
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.